Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EudraCT # : 2006-002482-39 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated acute otitis media or beta-hemolytic streptococcal pharyngo-tonsillitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug) |
|
| 2 | No Intervention | No treatment (reference group) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bacillus clausii | Drug | 2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes of microbial composition of fecal bacterial flora by PCR-DGGE analysis. | between samples obtained at baseline and follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Changes from baseline of body weight | During the total study period | |
| Assessment of abdominal symptoms | Daily | |
| Presence of Bacillus clausii spores in feces |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Georges Paizis, MD | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanofi-Aventis | Milan | Italy |
Not provided
| ID | Term |
|---|---|
| D005767 | Gastrointestinal Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C545326 | clausin peptide, Bacillus clausii |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| after heat shock treatment on selective medium. |
| Number and rate of patients with GI symptoms and time to first development of symptoms. | recorded in a daily diary card for the total study period |